For more information about TrialCard, please visit Contact:įor inquiries or corrections to Press Releases, please reach out to Cision.Seventeen African American (29%) and Latina women (71%) of average age 43 (☑0) years who had undergone RYGB surgery were followed for 4 years. The company is headquartered in Morrisville, North Carolina. Founded in 2000, TrialCard provides commercialization support for more than 400 life sciences customers and has connected over 36 million patients with more than $23 billion in branded drug savings to date. In addition to a foundation of fully integrated, digitally enabled patient support services, its broader offerings include everything from late-stage clinical trial supply management to post-marketing HCP engagement services and proprietary data-as-a-service payer intelligence and insights. TrialCard Incorporated is an integrated life sciences commercialization company that provides comprehensive solutions that span the entire biopharmaceutical value chain. TrialCard has held this certification since 2018. ISO/IEC 27001 certification is the gold standard in data security management and places TrialCard among the industry's best in data security and privacy. After a rigorous recertification process, TrialCard once again achieved the coveted ISO/IEC 27001 accreditation for its Information Security Management System (ISMS).This marks the twelfth time in its twenty-two-year history that TrialCard has been named a Fast 50 winner. In November, TrialCard was again recognized as one of the fastest-growing privately held companies in the Triangle area by the Triangle Business Journal (TBJ).September saw the introduction of Policy Reporter Partners, a new community of Reimbursement Opinion Leaders (ROLs) whose mission is to improve the access-to-treatment experience for patients through professional knowledge sharing. In October, it announced significant enhancements to its Formulary Viewer solution, which provides life sciences companies with access to a comprehensive database of drug formulary information. Policy Reporter, a TrialCard company, continued its impressive growth trajectory with 20% YOY growth.anti-kickback laws, which would make medications more accessible and affordable for all patients. Also in November, TrialCard filed an amicus brief in support of Pfizer's Supreme Court challenge of U.S. In November, TrialCard submitted comments to the FTC investigation into the harmful impact of Pharmacy Benefit Manager (PBM) practices on consumers. In January, TrialCard filed an amicus brief supporting a PhRMA lawsuit against the CMS Final Rule on manufacturer coupons and best price. Throughout 2022, TrialCard publicly supported many of the pharmaceutical industry's efforts to combat legislation and policies that adversely impact patients.In a career that has spanned over 20 years, Allocco has had repeated success in leading digital transformation efforts within large healthcare organizations. In September, TrialCard announced the appointment of James Allocco to Executive Vice President and Chief Technology Officer.Dulitz, a twenty-year veteran of the biopharma services industry, joined TrialCard in 2015 and had most recently served as President and Chief Strategy Officer, where he led TrialCard's efforts to acquire seven companies since 2018. In July, TrialCard's Board of Directors named Scott Dulitz Chief Executive Officer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |